Rodman & Renshaw Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $7

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $7.